With Vibrant VC Spending and Dry IPO Market, Regional Biotech Investment Trends Will Hold | GenomeWeb
A robust venture-capital market combined with a sluggish IPO environment will ensure that the pecking order among the nation’s biotech clusters won’t change, venture capitalists and other VC market watchers concluded in separate interviews last week.
 
“I think it’s going to continue to make [the existing leading geographic] markets the key markets” for biotech activity, said Tracy Lefteroff, global managing partner for life science industry services with PricewaterhouseCoopers.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.